daratumumab
janssen
['ifm 2018-04']
applaud the ifm 2018-04 study for including only high risk. upfront dara-krd + asct + dara-krd + asct #2. deep response with 62% mrd neg- but need to be careful with stem cell mobilization! please harvest cells as soon as possible for patients on upfront dara!! #asco2022 
Multiple Myeloma Oncologist